Tevogen Inc. (TVGN): Total Assets
$4.38M
As of 2025-12-31
$4.73M
As of 2026-06-30
-76.9%
3-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $4.38M | +26.6% | 2026-03-31, Balance as of period end |
| 2024-12-31 | $3.46M | -37.1% | 2026-03-31, Balance as of period end |
| 2023-12-31 | $5.51M | -98.5% | 2025-04-02, Balance as of period end |
| 2022-12-31 | $357.14M | +1.2% | 2024-04-29, Balance as of period end |
| 2021-12-31 | $352.85M | n/a | 2023-04-17, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Tevogen Inc. (TVGN) | 2025-12-31 | $4.38M | +26.6% |
| Eloxx Pharmaceuticals, Inc. (ELOX) | 2025-12-31 | $5.27M | +77.1% |
| Cero Therapeutics Holdings, Inc. (CERO) | 2025-12-31 | $3.64M | -41.3% |
| BioCardia, Inc. (BCDA) | 2025-12-31 | $3.41M | -8.4% |
| AIM ImmunoTech Inc. (AIM) | 2025-12-31 | $5.78M | -32.8% |
| Exozymes Inc. (EXOZ) | 2025-12-31 | $5.97M | -54.2% |
| Estrella Immunopharma, Inc. (ESLA) | 2025-12-31 | $3.18M | +1.2% |
| Silexion Therapeutics Corp (SLXN) | 2025-12-31 | $7.21M | +152.0% |
| VivoSim Labs, Inc. (VIVS) | 2026-03-31 | $7.39M | -49.6% |
Compare TVGN, ELOX, CERO, BCDA side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗